{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T02:48:36Z","timestamp":1788749316896,"version":"build-2803163510"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2024,8,16]],"date-time":"2024-08-16T00:00:00Z","timestamp":1723766400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,8,16]],"date-time":"2024-08-16T00:00:00Z","timestamp":1723766400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Objective: To investigate the diagnostic performance of liver stiffness for detecting liver involvement in immunoglobulin light chain (AL) amyloidosis. Methods: Liver stiffness was measured using transient elastography in 71 patients with systemic AL amyloidosis and 18 patients with wild type transthyretin (ATTRwt) amyloidosis with cardiomyopathy. Both non-invasive consensus criteria and serum amyloid P component (SAP) scintigraphy were used as substitute standards instead of liver biopsy for establishing liver involvement. Results: Liver stiffness was higher in AL amyloidosis patients with liver involvement than in those without: this was observed using both consensus criteria (median 14.4\u00a0kPa vs. 8.1\u00a0kPa;\n                    <jats:italic>p<\/jats:italic>\n                    \u2009=\u20090.001) and SAP scintigraphy (median 20.9\u00a0kPa vs. 6.2\u00a0kPa;\n                    <jats:italic>p<\/jats:italic>\n                    \u2009&lt;\u20090.001). Liver stiffness was also higher in AL amyloidosis patients with liver involvement compared to AL and ATTRwt amyloidosis patients with cardiac involvement. Based on receiver operating characteristic (ROC) curves a cut-off value of 14.4\u00a0kPa for stiffness was optimal to indicate liver involvement, providing sensitivity and specificity of 50% and 74%, respectively, using the consensus criteria and 63% and 90%, respectively, using SAP scintigraphy as standard. Conclusion: Liver stiffness is a promising tool to establish liver involvement in AL amyloidosis having potential to become part of updated criteria for liver involvement.\n                  <\/jats:p>","DOI":"10.1007\/s00277-024-05932-4","type":"journal-article","created":{"date-parts":[[2024,8,15]],"date-time":"2024-08-15T22:02:01Z","timestamp":1723759321000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Diagnostic performance of liver stiffness as marker of liver involvement in systemic immunoglobulin light chain (AL) amyloidosis"],"prefix":"10.1007","author":[{"given":"Anne F.","family":"Brunger","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hendrea S.A.","family":"Tingen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johan","family":"Bijzet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronald","family":"van Rheenen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans","family":"Blokzijl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wilfried W. H.","family":"Roeloffzen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ewout J.","family":"Houwerzijl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Friso L. H.","family":"Muntinghe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Riemer H. J. A.","family":"Slart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reinold O. B.","family":"Gans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christoph","family":"Kimmich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bouke P. C.","family":"Hazenberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans L. A.","family":"Nienhuis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,8,16]]},"reference":[{"key":"5932_CR1","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1200\/JCO.2011.38.5724","volume":"30","author":"S Kumar","year":"2012","unstructured":"Kumar S, Dispenzieri A, Lacy MQ et al (2012) Revised prognostic staging system for light chain amyloidosis incorporating cardiac biomarkers and serum free light chain measurements. J Clin Oncol 30:989\u2013995","journal-title":"J Clin Oncol"},{"key":"5932_CR2","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1097\/01.md.0000091183.93122.c7","volume":"82","author":"MA Park","year":"2003","unstructured":"Park MA, Mueller PS, Kyle RA et al (2003) Primary (AL) hepatic amyloidosis: clinical features and natural history in 98 patients. Med (Baltim) 82:291\u2013298","journal-title":"Med (Baltim)"},{"key":"5932_CR3","doi-asserted-by":"publisher","first-page":"2037","DOI":"10.1200\/JCO.2015.63.3123","volume":"34","author":"S Sachchithanantham","year":"2016","unstructured":"Sachchithanantham S, Roussel M, Palladini G et al (2016) European collaborative study defining clinical profile outcomes and novel prognostic criteria in monoclonal immunoglobulin M-related light chain amyloidosis. J Clin Oncol 34:2037\u20132045","journal-title":"J Clin Oncol"},{"key":"5932_CR4","doi-asserted-by":"publisher","first-page":"2343","DOI":"10.1517\/13543784.9.10.2343","volume":"9","author":"O Sezer","year":"2000","unstructured":"Sezer O, Niem\u00f6ller K, Jakob C et al (2000) Novel approaches to the treatment of primary amyloidosis. Expert Opin Investig Drugs 9:2343\u20132350","journal-title":"Expert Opin Investig Drugs"},{"key":"5932_CR5","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1097\/MEG.0b013e3283309d5b","volume":"22","author":"A Lanzi","year":"2010","unstructured":"Lanzi A, Gianstefani A, Mirarchi MG et al (2010) Liver AL amyloidosis as a possible cause of high liver stiffness values. Eur J Gastroenterol Hepatol 22:895\u2013897","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"5932_CR6","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1046\/j.1365-2141.2001.02999.x","volume":"114","author":"RA Kyle","year":"2001","unstructured":"Kyle RA (2001) Amyloidosis: a convoluted story. Br J Haematol 114:529\u2013538","journal-title":"Br J Haematol"},{"key":"5932_CR7","doi-asserted-by":"publisher","first-page":"1182","DOI":"10.1002\/hep.25993","volume":"57","author":"J Boursier","year":"2013","unstructured":"Boursier J, Zarski J-P, de Ledinghen V et al (2013) Determination of reliability criteria for liver stiffness evaluation by transient elastography. Hepatology 57:1182\u20131191","journal-title":"Hepatology"},{"key":"5932_CR8","doi-asserted-by":"publisher","first-page":"968","DOI":"10.1136\/gut.2006.111302","volume":"56","author":"M Fraquelli","year":"2007","unstructured":"Fraquelli M, Rigamonti C, Casazza G et al (2007) Reproducibility of transient elastography in the evaluation of liver fibrosis in patients with chronic liver disease. Gut 56:968\u2013973","journal-title":"Gut"},{"key":"5932_CR9","doi-asserted-by":"publisher","first-page":"19","DOI":"10.3109\/13506129.2010.543443","volume":"18","author":"V Loustaud-Ratti","year":"2011","unstructured":"Loustaud-Ratti V, Cypierre A, Rousseau A et al (2011) Non-invasive detection of hepatic amyloidosis: FibroScan, a new tool. Amyloid 18:19\u201324","journal-title":"Amyloid"},{"key":"5932_CR10","doi-asserted-by":"crossref","unstructured":"Gertz MA, Comenzo R, Falk RH et al (2005) Definition of organ involvement and treatment response in immunoglobulin light chain amyloidosis (AL): A consensus opinion from the 10th International Symposium on Amyloid and Amyloidosis. Am J Hematol. ;79:319\u2013328","DOI":"10.1002\/ajh.20381"},{"key":"5932_CR11","doi-asserted-by":"publisher","first-page":"947","DOI":"10.1053\/j.ajkd.2006.03.036","volume":"47","author":"C Sucker","year":"2006","unstructured":"Sucker C, Hetzel GR, Grabensee B et al (2006) Amyloidosis and bleeding: pathophysiology, diagnosis, and Therapy. Am J Kidney Dis 47:947\u2013955","journal-title":"Am J Kidney Dis"},{"issue":"8600","key":"5932_CR12","doi-asserted-by":"publisher","first-page":"1413","DOI":"10.1016\/S0140-6736(88)92235-0","volume":"1","author":"PN Hawkins","year":"1988","unstructured":"Hawkins PN, Myers MJ, Lavender JP, Pepys MB (1988) Diagnostic radionuclide imaging of amyloid: biological targeting by circulating human serum amyloid P component. Lancet 1(8600):1413\u20131418","journal-title":"Lancet"},{"key":"5932_CR13","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1056\/NEJM199008233230803","volume":"323","author":"PN Hawkins","year":"1990","unstructured":"Hawkins PN, Lavender JP, Pepys MB (1990) Evaluation of systemic amyloidosis by Scintigraphy with 123I-Labeled serum amyloid P component. N Engl J Med 323:508\u2013513","journal-title":"N Engl J Med"},{"key":"5932_CR14","doi-asserted-by":"publisher","first-page":"e15","DOI":"10.1016\/j.amjmed.2005.08.043","volume":"119","author":"BPC Hazenberg","year":"2006","unstructured":"Hazenberg BPC, Van Rijswijk MH, Piers DA et al (2006) Diagnostic performance of 123I-labeled serum amyloid P component scintigraphy in patients with amyloidosis. Am J Med 119:e15\u201324","journal-title":"Am J Med"},{"key":"5932_CR15","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1136\/gut.42.5.727","volume":"42","author":"LB Lovat","year":"1998","unstructured":"Lovat LB, Persey MR, Madhoo S et al (1998) The liver in systemic amyloidosis: insights from 123I serum amyloid P component scintigraphy in 484 patients. Gut 42:727\u2013734","journal-title":"Gut"},{"key":"5932_CR16","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1056\/NEJMoa2028631","volume":"385","author":"E Kastritis","year":"2021","unstructured":"Kastritis E, Palladini G, Minnema MC et al (2021) Daratumumab-based treatment for Immunoglobulin Light-Chain Amyloidosis. N Engl J Med 385:46\u201358","journal-title":"N Engl J Med"},{"key":"5932_CR17","doi-asserted-by":"publisher","first-page":"5126","DOI":"10.1182\/blood-2010-06-290668","volume":"116","author":"S Kumar","year":"2010","unstructured":"Kumar S, Dispenzieri A, Katzmann JA et al (2010) Serum immunoglobulin free light-chain measurement in primary amyloidosis: prognostic value and correlations with clinical features. Blood 116:5126\u20135129","journal-title":"Blood"},{"key":"5932_CR18","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1080\/13506129.2020.1714581","volume":"27","author":"AF Brunger","year":"2020","unstructured":"Brunger AF, Nienhuis HLA, Bijzet J et al (2020) A real-life cohort study of immunoglobulin light-chain (AL) amyloidosis patients ineligible for autologous stem cell transplantation due to severe cardiac involvement or advanced disease. Amyloid 27:119\u2013127","journal-title":"Amyloid"},{"key":"5932_CR19","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1080\/13506129.2018.1536043","volume":"25","author":"KHG Rutten","year":"2018","unstructured":"Rutten KHG, Raymakers RAP, Hazenberg BPC et al (2018) Haematological response and overall survival in two consecutive Dutch patient cohorts with AL amyloidosis diagnosed between 2008 and 2016. Amyloid 25:227\u2013233","journal-title":"Amyloid"},{"key":"5932_CR20","doi-asserted-by":"publisher","first-page":"904","DOI":"10.1016\/0046-8177(91)90180-W","volume":"22","author":"FS Buck","year":"1991","unstructured":"Buck FS, Koss MN (1991) Hepatic amyloidosis: morphologic differences between systemic AL and AA types. Hum Pathol 22:904\u2013907","journal-title":"Hum Pathol"},{"key":"5932_CR21","doi-asserted-by":"crossref","unstructured":"Brunger AF, van Rheenen R, Gans ROB, Hazenberg BPC, Nienhuis HLA (2023) How well does liver span as part of the consensus criteria for liver involvement in AL amyloidosis perform? Amyloid. (Online ahead of print).","DOI":"10.1080\/13506129.2023.2222878"},{"key":"5932_CR22","doi-asserted-by":"publisher","first-page":"e538","DOI":"10.1016\/S1470-2045(14)70442-5","volume":"15","author":"SV Rajkumar","year":"2014","unstructured":"Rajkumar SV, Dimopoulos MA, Palumbo A et al (2014) International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. Lancet Oncol 15:e538\u2013e548","journal-title":"Lancet Oncol"},{"key":"5932_CR23","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1002\/ejhf.2140","volume":"23","author":"P Garcia-Pavia","year":"2021","unstructured":"Garcia-Pavia P, Rapezzi C, Adler Y et al (2021) Diagnosis and treatment of cardiac amyloidosis. A position statement of the European Society of Cardiology Working Group on Myocardial and Pericardial diseases. Eur J Heart Fail 23:512\u2013526","journal-title":"Eur J Heart Fail"},{"key":"5932_CR24","first-page":"699","volume":"39","author":"PL Jager","year":"1998","unstructured":"Jager PL, Hazenberg BPC, Franssen EJF et al (1998) Kinetic studies with iodine-123-Labeled serum amyloid P component in patients with systemic AA and AL Amyloidosis and Assessment of Clinical Value. J Nucl Med 39:699\u2013706","journal-title":"J Nucl Med"},{"key":"5932_CR25","first-page":"785","volume":"33","author":"RWJ Van Rheenen","year":"2011","unstructured":"Van Rheenen RWJ, Glaudemans A, Hazenberg BPC (2011) Whole body amyloid deposition imaging by I-SAP scintigraphy. Tijdschr Voor Nucl Geneeskd 33:785\u2013791","journal-title":"Tijdschr Voor Nucl Geneeskd"},{"key":"5932_CR26","doi-asserted-by":"publisher","first-page":"865","DOI":"10.2967\/jnumed.106.039313","volume":"48","author":"BPC Hazenberg","year":"2007","unstructured":"Hazenberg BPC, van Rijswijk MH, Lub-de Hooge MN et al (2007) Diagnostic performance and Prognostic Value of Extravascular Retention of 123I-Labeled serum amyloid P component in systemic amyloidosis. J Nucl Med 48:865\u2013872","journal-title":"J Nucl Med"},{"key":"5932_CR27","doi-asserted-by":"publisher","first-page":"903","DOI":"10.1084\/jem.167.3.903","volume":"167","author":"PN Hawkins","year":"1988","unstructured":"Hawkins PN, Myers MJ, Epenetos AA et al (1988) Specific localization and imaging of amyloid deposits in vivo using 123I-labeled serum amyloid P component. J Exp Med 167:903\u2013913","journal-title":"J Exp Med"},{"key":"5932_CR28","doi-asserted-by":"publisher","first-page":"1413","DOI":"10.1016\/S0140-6736(88)92235-0","volume":"331","author":"PN Hawkins","year":"1988","unstructured":"Hawkins PN, Lavender JP, Myers MJ et al (1988) Diagnostic Radionuclide imaging of amyloid: Biological Targeting by circulating human serum amyloid P component. Lancet 331:1413\u20131418","journal-title":"Lancet"},{"key":"5932_CR29","first-page":"S208","volume":"43","author":"RWJ Van Rheenen","year":"2016","unstructured":"Van Rheenen RWJ, Hazenberg BPC, Noorzij W et al (2016) SPECT-based semi-quantitative assessment of I-123-SAP scintigraphy in patients with amyloidosis. Eur J Nucl Med Mol Imaging 43:S208","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"5932_CR30","doi-asserted-by":"publisher","first-page":"2317","DOI":"10.1038\/leu.2012.100","volume":"26","author":"RL Comenzo","year":"2012","unstructured":"Comenzo RL, Reece D, Palladini G et al (2012) Consensus guidelines for the conduct and reporting of clinical trials in systemic light-chain amyloidosis. Leukemia 26:2317\u20132325","journal-title":"Leukemia"},{"key":"5932_CR31","doi-asserted-by":"publisher","first-page":"872","DOI":"10.1148\/radiol.10100013","volume":"257","author":"A Colli","year":"2010","unstructured":"Colli A, Pozzoni P, Berzuini A et al (2010) Decompensated chronic heart failure: increased liver stiffness measured by means of transient Elastography. Radiology 257:872\u2013878","journal-title":"Radiology"},{"key":"5932_CR32","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1053\/j.gastro.2004.11.018","volume":"128","author":"L Cast\u00e9ra","year":"2005","unstructured":"Cast\u00e9ra L, Vergniol J, Foucher J et al (2005) Prospective comparison of transient elastography, Fibrotest, APRI, and liver biopsy for the assessment of fibrosis in chronic hepatitis C. Gastroenterology 128:343\u2013350","journal-title":"Gastroenterology"},{"key":"5932_CR33","first-page":"1223","volume":"87","author":"G Gregorini","year":"2015","unstructured":"Gregorini G, Izzi C, Ravani P et al (2015) Tubulointerstitial nephritus is a dominant feature of hereditary apolipoprotein A-I amyloidosis. Int Soc Nephrol 87:1223\u20131229","journal-title":"Int Soc Nephrol"},{"key":"5932_CR34","doi-asserted-by":"publisher","first-page":"4695","DOI":"10.1007\/s12325-023-02637-4","volume":"40","author":"ML Mauermann","year":"2023","unstructured":"Mauermann ML, Clarke JO, Litchy WJ et al (2023) Peripheral nervous, hepatic, and gastrointestinal endpoints for AL Amyloidosis clinical trials: report from the Amyloidosis Forum Multi-organ System Working group. Adv Therapy 40:4695\u20134710","journal-title":"Adv Therapy"},{"key":"5932_CR35","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1002\/hep.23425","volume":"51","author":"L Cast\u0301era","year":"2010","unstructured":"Cast\u0301era L, Foucher J, Bernard PH et al (2010) Pitfalls of liver stiffness measurement: a 5-year prospective study of 13,369 examinations. Hepatology 51:828\u2013835","journal-title":"Hepatology"},{"key":"5932_CR36","doi-asserted-by":"publisher","first-page":"1155","DOI":"10.7863\/jum.2003.22.11.1155","volume":"22","author":"W Kratzer","year":"2003","unstructured":"Kratzer W, Fritz V, Mason RA et al (2003) Factors affecting liver size. J Ultrasound Med 22:1155\u20131161","journal-title":"J Ultrasound Med"},{"key":"5932_CR37","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/13506129.2020.1868810","volume":"28","author":"G Palladini","year":"2021","unstructured":"Palladini G, Sch\u00f6nland SO, Sanchorawala V et al (2021) Clarification on the definition of complete haematologic response in light-chain (AL) amyloidosis. Amyloid 28:1\u20132","journal-title":"Amyloid"},{"key":"5932_CR38","doi-asserted-by":"publisher","first-page":"1393","DOI":"10.1200\/JCO.22.00643","volume":"41","author":"E Muchtar","year":"2023","unstructured":"Muchtar E, Dispenzieri A, Wisniowski B et al (2023) Graded Cardiac Response Criteria for patients with systemic light chain amyloidosis. J Clin Oncol 41:1393\u20131403","journal-title":"J Clin Oncol"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-024-05932-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00277-024-05932-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-024-05932-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,26]],"date-time":"2024-11-26T14:26:40Z","timestamp":1732631200000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00277-024-05932-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,16]]},"references-count":38,"alternative-id":["5932"],"URL":"https:\/\/doi.org\/10.1007\/s00277-024-05932-4","relation":{},"ISSN":["0939-5555","1432-0584"],"issn-type":[{"value":"0939-5555","type":"print"},{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,8,16]]},"assertion":[{"value":"14 March 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 August 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 August 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"None to declare.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All procedures were in compliance with the Declaration of Helsinki. The study was approved by the medical ethical committee of the University Medical Center Groningen (registration number: 17471).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}}]}}